Finlandiya - Fince - Fimea (Suomen lääkevirasto)

zentiva k.s. - sumatriptani succinas - tabletti - 100 mg - sumatriptaani

Finlandiya - Fince - Fimea (Suomen lääkevirasto)

zentiva group - tamsulosini hydrochloridum - depotkapseli, kova - 0.4 mg - tamsulosiini

Finlandiya - Fince - Fimea (Suomen lääkevirasto)

zentiva group - zolpidemi tartras - tabletti, kalvopäällysteinen - 10 mg - tsolpideemi

Finlandiya - Fince - Fimea (Suomen lääkevirasto)

zentiva a.s. - ondansetroni hydrochloridum dihydricum - tabletti, kalvopäällysteinen - 8 mg - ondansetroni

Finlandiya - Fince - Fimea (Suomen lääkevirasto)

zentiva, k.s. - ibuprofen - tabletti, kalvopäällysteinen - 400 mg - ibuprofeeni

Finlandiya - Fince - Fimea (Suomen lääkevirasto)

zentiva, k.s. - ibuprofen - tabletti, kalvopäällysteinen - 200 mg - ibuprofeeni

Avrupa Birliği - Fince - EMA (European Medicines Agency)

extrovis eu ltd. - lakosamidi - epilepsia - epilepsialääkkeet, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Avrupa Birliği - Fince - EMA (European Medicines Agency)

substipharm - prasugreeli - acute coronary syndrome; angina, unstable; myocardial infarction - antitromboottiset aineet - efient, yhteistyössä annostella asetyylisalisyylihappo (asa) on tarkoitettu ehkäisy atherothrombotic tapahtumista potilailla sepelvaltimotautikohtaus (i. epästabiili angina pectoris, ei st-segmentin nousua sydäninfarkti [ua / nstemi] tai st-segmentin nousua sydäninfarkti [stemi]) käynnissä ensisijainen tai viivästynyt perkutaaninen sepelvaltimotoimenpide (pci).

Avrupa Birliği - Fince - EMA (European Medicines Agency)

mabxience research sl - bevasitsumabi - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiset aineet - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Finlandiya - Fince - Fimea (Suomen lääkevirasto)

opella healthcare france sas - sodium cromoglicate - silmätipat, liuos - 20 mg/ml - natriumkromoglikaatti